The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | The benefits of liver transplantation & chemotherapy in colorectal liver metastases
Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, comments on the TRANSMET trial (NCT02597348), which assessed liver transplantation with chemotherapy or chemotherapy alone in patients with unresectable colorectal liver metastases. Addition of liver transplantation improved overall survival and progression-free survival, showing that this trial may be practice changing in this setting. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
